Marksans PharmaBOM:524404 -1.14%87 ROE % is 19.60% as of Mar. 2026, which is 18% above its 10-year median of 16.64. GuruFocus rates BOM:524404 with a GF Score™ of 87/100 and a GF Value™ of ₹227.28 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 933 Drug Manufacturers companies, Marksans Pharma ranks better than 78.99% on this metric.
The historical rank and industry rank for Marksans Pharma's ROE % or its related term are showing as below:
BOM:524404'
s ROE % Range Over the Past 10 Years
Min: 2.01 Med: 16.64 Max: 31.33
Current: 15.33
During the past 13 years, Marksans Pharma's highest ROE % was 31.33%. The lowest was 2.01%. And the median was 16.64%.
BOM:524404's ROE % is ranked better than 78.99% of 933
companies
in the Drug Manufacturers industry
Industry Median: 6
vs BOM:524404: 15.33
Marksans Pharma (BOM:524404) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Marksans Pharma ROE % Related Terms
Marksans Pharma ROE % Historical Data
* Premium members only.
The historical data trend for Marksans Pharma's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Marksans Pharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marksans Pharma ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's ROE % distribution charts can be found below:
* The bar in red indicates where Marksans Pharma's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Marksans Pharma (BOM:524404) has a ROE % of 19.60% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Marksans Pharma and its competitors. This is 18% above median its historical median of 16.64. Over the past decade, Marksans Pharma's ROE % has ranged from 2.01 to 31.33. According to the industry distribution chart, Marksans Pharma ranks #196 out of 933 companies in the Drug Manufacturers industry, placing it in the top 21%.
Is Marksans Pharma's ROE % too high?
Marksans Pharma's current ROE % of 19.60% is 18% above median its 10-year median of 16.64. Over the past 10 years, this metric has ranged from a low of 2.01 to a high of 31.33. The Drug Manufacturers industry median ROE % is 6.00. Marksans Pharma's value of 19.60% is 226.7% above this industry median. Based on the distribution chart, Marksans Pharma ranks #196 out of 933 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Marksans Pharma has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's ROE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Marksans Pharma ranks #196 out of 933 companies for ROE %. This places Marksans Pharma in the top 21% of its industry — outperforming the majority of peers. The industry median ROE % is 6.00. Marksans Pharma's value of 19.60% is 226.7% above this benchmark. Historically, Marksans Pharma's own ROE % has ranged from 2.01 to 31.33 over the past decade. While the company's 10-year median is 16.64 vs. the industry median of 6.00, Marksans Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marksans Pharma's current ROE % of 19.60% is 226.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Marksans Pharma and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marksans Pharma's current ROE % is 19.60%, which is 18% above median its own 10-year median of 16.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹227.28, compared to a current price of ₹264.00 — trading 16.2% above its estimated fair value. The current ROE % is 19.60%, which is 18% above median its 10-year median of 16.64 and 226.7% above the Drug Manufacturers industry median of 6.00. Marksans Pharma's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current ROE % is 19.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marksans Pharma (BOM:524404) Overvalued in 2026?
Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued.
The current stock price of ₹264.00 is trading 16.2% above its estimated GF Value™ of ₹227.28.
GuruFocus considers Marksans Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524404:
ROE %: 19.60% (18% above median its 10-year median of 16.64)
GF Value™: ₹227.28 vs. price of ₹264.00 (16.2% above fair value)
Industry Position: 226.7% above the Drug Manufacturers median (#196 of 933)
No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
87GF Score
Get the complete analysis for BOM:524404
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524404 has been successfully added to your 
